# SENS earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SENS) · [Earnings tab](https://www.lopjlb.com/stock/SENS?tab=earnings)

Updated: 2026-11-09T05:22:08

Quarters analyzed: 8

## Cross-quarter narrative

Across the eight earnings calls, Senseonics moved from a quiet early‑year stance to a clear trajectory of commercial expansion and financial strengthening. The company debuted the Eversense 365 system in the U.S. (Q4 2024) and quickly filed for EU CE marking, culminating in a European launch by Q4 2025. Revenue accelerated from $6.3 M in Q1 2025 to $11.7 M in Q1 2026, prompting upward revisions to FY25 and FY26 guidance. Gross margins rose from just above 25% to 58% as product mix improved and DTC marketing boosted patient adoption. The pipeline advanced with a Gemini IDE submission in late 2024, an IDE study slated for late 2025, and Freedom’s first‑in‑human trial targeted for H2 2026. A major commercial transition from Ascensia was completed in the U.S. and is on track in Europe. Capital raised grew from $78 M in Q2 2025 to over $100 M in Q1 2026, extending runway to mid‑2027. Payer dynamics improved with Medicare reimbursement secured and commercial payer conversion exceeding 50%. Overall, the calls reflect accelerating product rollout, strengthening financials, and steady progress on key regulatory milestones.

## Latest CallCard · Q1

Senseonics raised 2026 revenue guidance to $60-64M after Q1 $11.7M revenue and 58% gross margin; U.S. commercial integration complete, Europe transitioning; Gemini on track for H1 2027, Freedom first-in-human H2 2026; $100M+ financing strengthens balance sheet.','tone': {'mgmt': 0.8, 'mgmt_rationale

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Senseonics raised 2026 revenue guidance to $60-64M after Q1 $11.7M revenue and 58% gross margin; U.S. commercial integration complete, Europe transitioning; Gemini on track for H1 2027, Freedom first-in-human H2 2026; $100M+ financing strengthens balance sheet.','tone': {'mgmt': 0.8, 'mgmt_rationale
- **2025 Q4:** Senseonics completed commercial transition from Ascensia, launched Eversense 365 in EU, guided 65-76% revenue growth to $58-62M in 2026 with >50% gross margins, advancing Gemini/Freedom pipeline.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management emphasizes successful transformation, 60% revenue g
- **2025 Q3:** Senseonics Q3 revenue surged 90% YoY to $8.1M on 160% new patient shipment growth; DTC marketing drives 90% switcher rate; Ascensia transition on track for Jan 1 US, H1 2026 EU; margins improving to 35-40% FY25, targeting 50% FY26; $35M FY25 revenue guidance.','tone':{'mgmt':0.8,'mgmt_rationale':'Pr
- **2025 Q2:** Senseonics Q2: Eversense 365 launch accelerating (new starts +79% YoY), $78M raised, 2025 revenue guidance $34-38M maintained, Gemini IDE study late 2025, Freedom ~1yr after Gemini, Eon Care expanding to 50 inserters by year-end.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlights 79% Yo
- **2025 Q1:** Senseonics Q1 rev $6.3M (+24%), maintains $34-38M FY25 guide; Eversense 365-twiist AID integration, EU CE Mark filed for H2 launch; Medicare reimbursement secured, commercial payer conversion >50%; cash $64.6M, runway mid-2026.','tone': {'mgmt': 0.6, 'mgmt_rationale': 'Management highlights multiple
- **2024 Q4:** Senseonics launched Eversense 365 in US, filed CE Mark for EU H2 2025 launch; patient base grew 56% to ~6K, prescribers up 73%; pipeline advancing with Gemini IDE submission by year-end and Freedom development; Q4 revenue $8.3M, gross margin >25% on 365; 2025 guidance given but details limited.','to
- **2024 Q3:** —
- **2024 Q2:** —

## Theme arcs

- **Product launch acceleration** (improving): Eversense 365 US launch followed by rapid EU rollout and strong new‑start growth
- **Revenue growth** (improving): Quarterly revenue climbed from $6.3 M to $11.7 M, guidance lifted
- **Gross margin improvement** (improving): Margins rose from >25% to 58% as mix and pricing improved
- **Pipeline progression** (improving): Gemini IDE submitted, IDE study scheduled, Freedom first‑in‑human planned
- **Commercial transition (Ascensia)** (resolved): U.S. transition completed, EU transition on track
- **Capital infusion** (improving): $78 M raised in Q2 2025, >$100 M in Q1 2026 extended runway
- **Payer reimbursement** (new): Medicare secured and >50% commercial payer conversion

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SENS`